195 results on '"Nevill T"'
Search Results
2. An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring
3. Topic: AS09-Quality of life-Disease experiences: LONGITUDINAL TRAJECTORY OF QUALITY OF LIFE IN MDS AND IMPACT OF PATIENT-RELATED FACTORS
4. Topic: AS02-Epidemiology: EVALUATION OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE COHORT STUDY FROM THE CANADIAN MDS REGISTRY
5. The changing rationalities of Australian federal and national inclusive education policies
6. P143 - Topic: AS09-Quality of life-Disease experiences: LONGITUDINAL TRAJECTORY OF QUALITY OF LIFE IN MDS AND IMPACT OF PATIENT-RELATED FACTORS
7. P025 - Topic: AS02-Epidemiology: EVALUATION OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE COHORT STUDY FROM THE CANADIAN MDS REGISTRY
8. P542: REAL WORLD OUTCOMES FOR PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN BRITISH COLUMBIA (BC): EXCELLENT OUTCOMES WITH LOW EARLY DEATH RATE AND HIGH OVERALL SURVIVAL IN A POPULATION BASED STUDY
9. P59 - Topic: AS08-Treatment/AS08j-Supportive care - Iron overload: MDS IRON ROAD: AN INTERNET-BASED ALGORITHM FOR THE DIAGNOSIS, WORKUP AND MANAGEMENT OF IRON OVERLOAD IN MDS FROM THE CANADIAN CONSORTIUM ON MDS (CCMDS)
10. P09 - Topic: AS02-Epidemiology: THE IMPACT OF GAINING OR LOSING TRANSFUSION INDEPENDENCE ON QUALITY OF LIFE IN MYELODYSPLASTIC SYNDROMES
11. Topic: AS08-Treatment/AS08j-Supportive care - Iron overload
12. Topic: AS02-Epidemiology
13. Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study
14. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens
15. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results
16. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML
17. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease
18. Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation
19. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis
20. Stem cell transplantation for myelofibrosis: a report from two Canadian centers
21. Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation
22. High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease
23. Donor leukocyte infusions for multiple myeloma
24. Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia
25. Induction therapy with high-dose dexamethasone alone in newly diagnosed myeloma patients produces a high partial response rate which is predictive of progression free and overall survival: 113
26. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes
27. 15. Clinical Results in Lymphoma II: 069 MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO HSCT) FOR NON-HODGKINʼS LYMPHOMA (NHL): 20-YEAR EXPERIENCE WITH FAMILY MEMBER AND VOLUNTEER UNRELATED DONORS (UD)
28. Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22)
29. Allografting for indolent lymphoid neoplasms
30. An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring
31. Bone marrow transplantation for adults with acute leukaemia and 11q23 chromosomal abnormalities
32. Normal CD5+ B lymphocytes are poor stimulators in the autologous mixed lymphocyte reaction (AMLR)
33. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
34. P-116 Frailty is an independent prognostic marker for overall survival in MDS: Results of a Canadian MDS registry
35. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome
36. High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease
37. Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study
38. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens
39. Territorial Army
40. Complex Volcanic Reservoir Characterization - A Case Study for Southern Songliao Basin, Northeast China
41. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia
42. Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease with Rabbit Antithymocyte Globulin
43. Development of a Biologically Distinct EBV-Related Lymphoproliferative Disorder Following Autologous Bone Marrow Transplantation for an EBV-Negative Post-Renal Allograft Burkitt's Lymphoma
44. RETURN TO DURABLE DONOR HAEMATOPOIESIS AFTER BLAST PHASE RELAPSE OF CHRONIC MYELOID LEUKAEMIA FOLLOWING MARROW TRANSPLANTATION
45. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
46. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation.
47. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
48. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
49. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease.
50. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.